Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label study of vemurafenib in metastatic melanoma with brain metastases
NL-OMON37956Phase 2Active, not recruiting
- Sponsor
- Roche
- Start
- Dec 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vemurafenib in melanoma and brain metastases, sponsored by Roche. Primary endpoint: Best Overall Response Rate in the brain. Started Dec 2011; status: active, not recruiting.
02
Drugs
vemurafenib
03
Conditions
melanomabrain metastases
Beyond the preview
Go deeper on NL-OMON37956.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON37956.